Document ID: chunk:federal_register_of_legislation:F2018L01182:schedule:1:p2
Version: federal_register_of_legislation:F2018L01182
Segment Type: schedule
Provision Reference: sch 1 (pt 2/3)
Character Range: 16738–20573

fluticasone propionate;
         (e)          4 000 micrograms of triamcinolone; or
         (f)           a therapeutically equivalent dose of another inhaled glucocorticoid.
                                     extreme heat means 40 degrees Celsius or above.
                                     glucocorticoid therapy as specified means:
         (a)          applying a high or very high potency topical glucocorticoid to at least 10% of total skin surface area, daily, for a continuous period of at least three months; or
         (b)          inhaling at least 1 600 micrograms of budesonide, or equivalent inhaled glucocorticoid, daily, for a continuous period of at least three months; or
         (c)           taking:
            (i)             hydrocortisone, orally or by injection:
                (A)         to a cumulative dose of at least 600 milligrams; and
                (B)         at a minimum dose rate averaging 20 milligrams per day, or
            (ii)         equivalent glucocorticoid therapy, orally or by injection; or
         (d)          using a glucocorticoid concurrently with a drug, daily, for at least four weeks, where that drug can inhibit the activity of the metabolising enzyme cytochrome P450 3A4 by at least 30% (moderate to strong inhibition); or
         (e)          using a glucocorticoid concurrently with a drug from Specified List 2 of drugs, daily, for a continuous period of at least four weeks; or
         (f)           using an ocular glucocorticoid, daily, for a continuous period of at least six months; or
         (g)          using an intranasal glucocorticoid, at an average daily dose exceeding 400 micrograms of betamethasone 0.1%, or equivalent intranasal glucocorticoid, for a continuous period of at least six months; or
         (h)          using glucocorticoid containing enemas, daily, for a continuous period of at least six months; or
         (i)            taking any glucocorticoid therapy that causes Cushing syndrome.
        Note:               equivalent glucocorticoid therapy, equivalent inhaled glucocorticoid, high or very high potency topical glucocorticoid and Specified List 2 of drugs are also defined in the Schedule 1 – Dictionary.
                                     high or very high potency topical glucocorticoid means:
         (a)          betamethasone dipropionate 0.05%;
         (b)          betamethasone valerate 0.1%;
         (c)          clobetasol proprionate 0.05%;
         (d)          diflucortolone valerate 0.1%;
         (e)          fluocinolone acetonide 0.025%;
         (f)           methylprednisolone 0.1%;
         (g)          mometasone 0.1%;
         (h)          triamcinolone acetonide 0.5%; or
         (i)            another topical glucocorticoid of equivalent potency.
                                              iron overload means an accumulation of excess iron in tissues and organs which has been confirmed by elevated ferritin or transferrin saturation levels.  Causes include haemochromatosis or blood transfusions.
                                              MET means a unit of measurement of the level of physical exertion.  1 MET = 3.5 ml of oxygen/kg of body weight per minute, 1.0 kcal/kg of body weight per hour or resting metabolic rate.
                                              MRCA means the Military Rehabilitation and Compensation Act 2004.
                                              relevant service means:
         (a)          operational service under the VEA;
         (b)          peacekeeping service under the VEA;
         (c)          hazardous service under the VEA;
         (d)          British nuclear test defence service under the VEA;
         (e)          warlike service under the MRCA; or
         (f)           non-warlike service under the MRCA.
Note: